Metabolic Syndrome Accompanied by Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes
Authors:
- 1 September 2005
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 28 (9) , 2211-2216
Abstract
OBJECTIVE—To determine whether plasma concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI) in patients with type 2 diabetes were associated with components of metabolic syndrome (MS), including high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor (PAI)-1, and LDL cholesterol. RESEARCH DESIGN AND METHODS—We studied 136 consecutive patients with type 2 diabetes. Diagnosis of MS was diagnosed by current criteria. Hypercholesterolemia (HC) was defined as serum LDL cholesterol >140 mg/dl (3.6 mmol/l) or treatment with a statin. For comparisons, diabetic patients were divided into four groups: those with no MS and no HC (n = 38), with MS but not HC (n = 39), with no MS but with HC (n = 26), and with both MS and HC (n = 33). RESULTS—Considering all patients with type 2 diabetes, plasma PAI-1 was strongly associated with MS components such as BMI, triglyceride, alanine aminotransferase, a homeostasis model assessment of insulin resistance, and hs-CRP. Plasma TAFI only correlated positively and independently with LDL cholesterol. Plasma concentrations of plasmin-α2-antiplasmin complex (PAP), a measure of fibrinolytic activity in blood, showed a significant negative correlation with plasma PAI-1 but not TAFI. Diabetic patients with both MS and HC had the highest serum hs-CRP concentrations and the lowest plasma PAP concentrations. CONCLUSIONS—LDL cholesterol is a main determinant of plasma TAFI in patients with type 2 diabetes. Coexistence of MS and HC synergistically accelerates inflammation and impairment of fibrinolysis via elevated concentrations of both TAFI and PAI-1, which inhibit fibrinolysis.Keywords
This publication has 31 references indexed in Scilit:
- Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1International Journal of Obesity, 2004
- Enhancement of Fibrinolysis in Poorly Controlled, Hospitalized Type 2 Diabetic Patients by Short-Term Metabolic Control: Association with a Decrease in Plasminogen Activator Inhibitor 1Experimental and Clinical Endocrinology & Diabetes, 2004
- Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseasesJournal of Internal Medicine, 2004
- Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular DiseaseCirculation, 2003
- Deficiency of Thrombin Activatable Fibrinolysis Inhibitor in Cirrhosis Is Associated With Increased Plasma FibrinolysisHepatology, 2003
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndromeJournal of Thrombosis and Haemostasis, 2003
- Fluvastin therapy affects TAFI concentration in kidney transplant recipientsTransplant International, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Impact of Adipose Tissue on Plasma Plasminogen Activator Inhibitor-1 in Dieting Obese WomenArteriosclerosis, Thrombosis, and Vascular Biology, 1999